Myanmar Case Study: Increasing Access to HIV Treatment. Mburu G, Paing AZ, Myint NN, Wang B, et al. (2016)

immage

There has been a rapid increase in the number of people living with HIV in Myanmar over the last decade, the majority of who are eligible for treatment. Alongside this increase has been an effort by the ministry of health to rapidly scale up provision of treatment in order to reduce HIV-related illnesses and deaths.

However, Myanmar has an ambitious national strategic goal of providing ART to 106,058 people by the end of 2016. The health system in Myanmar is already stretched, and to achieve this goal, innovation in ART delivery will be required in-order to ensure that ART is provided close to communities, without compromising quality.


Keywords: HIV, ART, healthcare, CD4 count, treatment

 

Download publication

 

Review on the Epidemiology and Prevention and Control of Hepatitis A. Centre for Health Protection, Department of Health. (2016)

immage

This paper reviews the latest global and local situation of hepatitis A and examines the prevention and control measures of hepatitis A in Hong Kong.

Hepatitis A is inflammation of the liver caused by the hepatitis A virus (HAV). It is one of the most frequent causes of foodborne infection. It occurs sporadically and in epidemics worldwide. Every year there are an estimated 1.4 million cases of hepatitis A worldwide. Regions with high HAV endemicity include parts of Africa and Asia.


Keywords: Hong Kong, Hepatitis A, Hepatitis B, treatment, mode of transmission

 

Download Publication

Enhancing Linkage to Care of People Living with HIV (PLHIV). Department of Health, Philippines. (2016)

immage

Data from the DOH - Epidemiology Bureau shows that only 44o/o of allpeople diagnosed with HIV from 2010 to 2015 were started on Anti-Retroviral Therapy (ART). Based on the 2013 external evaluation of the health sector's response to HIV in the Philippines, long turn-around time of confirmatory HIV testing is one of the identified barriers for prompt referral and management. In the interim, this memorandum shall ensure linkage to care of clients with reactive HIV screening test to immediately be assessed by Treatment hubs, satellite treatment hubs and HIV primary care clinics in order to provide early treatment and management.

 

 

Download Document

Untangling the Web of Antiretroviral Price Reductions. Medecins Sans Frontieres (MSF). (2016)

immage

The report finds that prices of older HIV drugs continue to decline, while newer drugs remain largely priced out of reach. This is in large part because pharmaceutical corporations maintain monopolies that block price-lowering generic competition.

Today, the lowest available price for a quality-assured, World Health Organization-recommended first-line one-pill-a-day combination is US$100 per person per year (tenofovir/emtricitabine/efavirenz). This is a decrease of 26 per cent since MSF last recorded the lowest price for first-line treatment at US$136 in 2014. For a WHO-recommended second-line regimen, the lowest available price is now US$286 per person per year (zidovudine/lamivudine + atazanavir/ritonavir) – an 11 per cent decrease from US$322 two years ago.


Keywords: HIV, ARV, treatment, access, adults, children

 

Download Publication

Policy Brief: WHO Recommends Assistance for People with HIV to Notify their Partners. WHO. (2016)

immage

The sexual partners and drug injecting partners of people diagnosed with HIV infection have an increased probability of also being HIV-positive.
Assisted HIV partner notification services are a simple and effective way to reach these partners, many of whom are undiagnosed and unaware of their HIV exposure, and may welcome support and an opportunity to test for HIV.
Assisted partner notification has been an important public health approach in infectious disease management for decades, including in programmes for sexually transmitted infections and tuberculosis, but has not been routinely implemented for people with HIV.


Keywords: HIV, partner, public health, testing, services

 

Download Publication

 

Infographics: World Antibiotic Awareness Week. WHO. (2016)

immage

This year World Antibiotic Awareness Week will be held from 14 to 20 November 2016. The campaign aims to increase awareness of global antibiotic resistance and to encourage best practices among the general public, health workers, policy-makers and the agriculture sector to avoid the further emergence and spread of antibiotic resistance.


Download Infographics


- Causes of antibiotic resistance

 

- How it spreads

 

- What you can do

 

- What policy makers can do

 

- What the agriculture sector can do

 

- What health workers can do

 

- What dentists can do

 

- What doctors can do

 

- What hospital and clinic managers can do

 

- What midwives can do

 

- What nurses can do

 

- What pharmacists can do

Progress Report 2016 - Prevent HIV, Test and Treat All. WHO (2016)

immage

The global HIV epidemic claimed fewer lives in 2015 than at any point in almost two decades, and fewer people became newly infected with HIV than in any year since 1991. The list of countries on the brink of eliminating new HIV infections among children keeps growing. A massive expansion of antiretroviral therapy (ART) has reduced the global number of people dying from HIV-related causes to about 1.1 million in 2015 – 45% fewer than in 2005. UNAIDS/WHO estimates show that more than 18 million people were receiving ART in mid-2016.


Keywords: HIV, Fast-Track, 90-90-90, public health, prevention, testing

 

Download Publication

WHO Essential Medicines and Health Products Annual Report 2015. WHO/EMP. (2016)

immage

2015 confirmed a significant recent trend in the flagship WHO Model List of Essential Medicines with groundbreaking new treatments for hepatitis C and a variety of cancers included in the list despite their high prices. The list also included five new medicines for multidrug resistant tuberculosis (TB), among other updates. Traditionally considered a tool for developing countries to use as a guide for national medicines selection, the WHO Essential Medicines List is increasingly seen as a tool to increase access globally.


Keywords: HIV, AIDS, treatment, hepatitis C, tuberculosis (TB), drug resistant

 

Download Publication

HIV/HCV Co-infection Strategic Narrative. UNITAID. (2016)

immage

Until recently, diagnosis and treatment of HCV was complex. Suitable tools for screening and diagnosis were lacking, and treatment was hampered by limited efficacy and severe side effects. New medicines for the treatment of HCV have revolutionized HCV treatment. Combinations of these new medicines, which are generally well-tolerated and effective, can cure HCV in 12 weeks. This offers a huge opportunity to address HCV, in particularly among HIV/HCV co-infected people, who are more vulnerable as they progress faster to serious disease than HCV mono-infected people.


Keywords: HIV, HCV, medicines, treatment, diagnosis, prevention

 

 

Download Publication 

Global Action Plan for HIV Drug Resistance 2016-2021. WHO. (2016)

immage

The World Health Organization (WHO) is committed to ensuring that the great success of HIV treatment scale-up is not threatened by HIV drug resistance (HIVDR). Preventing HIVDR is an important part of meeting the 90-90-90 targets by the year 2020.

The development of a five-year plan reflects a global consensus that HIVDR in lower and middle-income countries requires a coordinated and resourced response. The Global Action Plan is an agreement by key partners about their respective roles in preventing, monitoring, and responding to HIVDR.


Keywords: HIV, ART, treatment, prevention, drug-resistant

 

Download Publication

Pages

Data Dashboard
database
Highlighted publications
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Global_TB_Report_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal_National_Community_Led_HIV_Testing_Guidelines_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_IBBS_PWID_PWUD_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_IBBS_FEW_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/DataHub_TB-HIV_Fact_Sheet_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Monitoring_2018.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NSACP_Sri_Lanka_National_HIV_Communication_Strategy_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_Status_of_National_AIDS_Response_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V1_North-East_region_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V2_West_South_region_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V3_Northern_Central_Eastern_region_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_Annual_report_2016-17.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_Estimations_and_projections_of_HIV_AIDS_at_Sub-national_level_2016-2020.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_HIV_drug_resistance_report_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_on_public_health_response_to_pretreatment_HIV_drug_resistance_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_for_Managing_Advanced_HIV_Disease_and_Rapid_Initiation_of_ART_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_What_New_in_Treatment_Monitoring_Viral_Load_and_CD4_Testing_2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_IBBS_2016-17.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_Mapping_Key_Populations_2015-16.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Update_2017_Data_2017_en.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Myanmar_National_Strategic_Plan_on_HIV_and_AIDS_2016-2020.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_2017_Global_AIDS_Monitoring_2016.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal-IBBS-FIDU-Kathmandu-valley-RI-2016.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_methods_for_deriving_estimates_2016.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_Size_Estimation_of_Key_Affected_Populations_in_Philippines.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Assessment_of_Decentralization_of_ART_in_MMR_2016.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-2016-prevention-gap-report_en.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Implementing_comprehensive_HIV_and_STI_programmes_with_transgender_people_2016.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/Philippines_2015_IHBSS_Fact_Sheets_Nov2017.pdf
https://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Consolidated_on_the_use_of_antiretroviral_drugs_for_treating_and_preventing_HIV_infection_2016.pdf
Calendar of events
Nov
20
Dec
1
(1 Dec - 1 Dec)